Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories

Détails

ID Serval
serval:BIB_0C94D0884781
Type
Autre: (aucun autre type ne convient)
Collection
Publications
Titre
Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories
Auteur⸱e⸱s
Su Yapeng, Chen Daniel, Lausted Christopher, Yuan Dan, Choi Jongchan, Dai Cheng, Voillet Valentin, Scherler Kelsey, Troisch Pamela, Duvvuri Venkata R., Baloni Priyanka, Qin Guangrong, Smith Brett, Kornilov Sergey, Rostomily Clifford, Xu Alex, Li Jing, Dong Shen, Rothchild Alissa, Zhou Jing, Murray Kim, Edmark Rick, Hong Sunga, Jones Lesley, Zhou Yong, Roper Ryan, Mackay Sean, O'Mahony D. Shane, Dale Christopher R, Wallick Julie A, Algren Heather A, Michael Zager A, Magis Andrew, Wei Wei, Price Nathan D., Huang Sui, Subramanian Naeha, Wang Kai, Hadlock Jennifer, Hood Leroy, Aderem Alan, Bluestone Jeffrey A., Lanier Lewis L., Greenberg Phil, Gottardo Raphael, Davis Mark M., Goldman Jason D., Heath James R.
Date de publication
2020
Langue
anglais
Résumé
Host immune responses play central roles in controlling SARS-CoV2 infection, yet remain incompletely characterized and understood. Here, we present a comprehensive immune response map spanning 454 proteins and 847 metabolites in plasma integrated with single-cell multi-omic assays of PBMCs in which whole transcriptome, 192 surface proteins, and T and B cell receptor sequence were co-analyzed within the context of clinical measures from 50 COVID19 patient samples. Our study reveals novel cellular subpopulations, such as proliferative exhausted CD8 (+) and CD4 (+) T cells, and cytotoxic CD4 (+) T cells, that may be features of severe COVID-19 infection. We condensed over 1 million immune features into a single immune response axis that independently aligns with many clinical features and is also strongly associated with disease severity. Our study represents an important resource towards understanding the heterogeneous immune responses of COVID-19 patients and may provide key information for informing therapeutic development.
Pubmed
Création de la notice
28/02/2022 11:45
Dernière modification de la notice
23/03/2024 7:24
Données d'usage